In a study by Wilson et al. [110], a small group of patients with early stage, high-grade serous ovarian cancer was analyzed for IgG-, IgA-, and IgM-mediated autoantibody reactivity, and a high content of IgA auto-antibodies in early stage rather than late-stage disease was highlighted, suggesting they may be useful early indicators. This evidence concerns the gene CD79A and ovarian serous adenocarcinoma.